The current financial score of Legend Biotech Corp is 8.58. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 387.50M, representing a year-over-year increase of 51.93%, while its net profit experienced a year-over-year increase of 126.48%.
The current valuation score of Legend Biotech Corp is 9.62. Its current P/E ratio is -13.76, which is -24.19% below the recent high of -10.43 and -197.97% above the recent low of -41.01.
The current earnings forecast score of Legend Biotech Corp is 8.12. The average price target is 50.46, with a high of 74.00 and a low of 24.00.
The current price momentum score of Legend Biotech Corp is 4.62. Currently, the stock price is trading between the resistance level at 21.51 and the support level at 16.32, making it suitable for range-bound swing trading.
The current institutional shareholding score of Legend Biotech Corp is 5.00. The latest institutional shareholding proportion is 50.74%, representing a quarter-over-quarter increase of 4.74%. The largest institutional shareholder is Matthews International Capital Management, holding a total of 917.27K shares, representing 9.08% of shares outstanding, with 43.81% increase in holdings.
The current risk assessment score of Legend Biotech Corp is 5.24. The company's beta value is 0.36. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.